Tirzepatide (GLP-2) 30mg

TirzepatideStructure Imiterere ya

Research Ubushakashatsi bwa Tirzepatide

Ni ubuhe bushakashatsi bwakozwe na Tirzepatide?

Ubushakashatsi bwakozwe na Tirzepatide buturuka ahanini ku bushakashatsi ku miti ivura metabolism no gukenera imiti igabanya ibiro. Imiti gakondo ivura metabolism ifite aho igarukira, mugihe GLP-1 yakira reseptor agoniste yerekana akamaro gakomeye mugutezimbere glucose yamaraso, bigatuma abashakashatsi bakora imiti ikora neza murwego rumwe. Nka GIP / GLP-1 dual reseptor agonist, Tirzepatide irashobora kugenzura neza urugero rwa glucose yamaraso. Ubwiyongere bw'isi ku baturage bafite umubyibuho ukabije n'umubyibuho ukabije byatumye kugenzura ibiro bikenerwa byihutirwa kwa muganga. GLP-1 reseptor agonist igira ingaruka zo kugabanya ibiro, bigatuma iba intego yo kugabanya ibiro. Tirzepatide yitabiriwe cyane kubera ingaruka nziza zo kugabanya ibiro.

Nubuhe buryo bwo gukora bwa Tirzepatide?

Ibikorwa bibiri byakira agonist: 

Tirzepatide ni glucagon ebyiri isa na peptide-1 (GLP-1) hamwe na glucose iterwa na insulineotropic polypeptide (GIP) reseptor agonist [1,2] (Wong E, 2023; Kumar D, 2022). GLP-1 na GIP byombi ni imisemburo ya incretin ikorwa mu mara, igira uruhare runini mukubungabunga glucose homeostasis. Tirzepatide igira uruhare runini mugukoresha icyarimwe GLP-1 na GIP yakira, bityo bikagabanya urugero rwa glucose yamaraso.

Kugena imisemburo ya insuline na glucagon: 

Yongera insuline ya insuline no gusohora mugihe igabanya glucagon muburyo bwa glucose. Iyo glucose yamaraso yiyongereye, Tirzepatide itera pancreatic β-selile gusohora insuline, igatera glucose no kuyikoresha, bityo bikagabanya urugero rwa glucose yamaraso; icyarimwe, irabuza pancreatic α-selile gusohora glucagon, kugabanya umusaruro wa glucose ya hepatike, kurushaho kugabanya urugero rwa glucose yamaraso, no kugenzura neza igisibo n’amaraso ya glucose nyuma y’inyuma ^[1,3].

Ubundi buryo bwibikorwa: 

Tirzepatide kandi iteza imbere guhaga, bishobora kuba bifitanye isano no gukora reseptor ya GLP-1, gukora kuri sisitemu yo hagati y’imyakura, no kugira ingaruka ku bigo bigenzura ibyokurya, bigatuma abarwayi bagabanya ibiryo bityo bagafasha mu kugabanya ibiro. Iradindiza kandi gusiba gastric, ikongerera igihe ibiryo biguma mu gifu kandi ikinjira buhoro buhoro mu mara mato, bityo bikarinda kwiyongera byihuse mu maraso ya glucose ^[1].

Igishushanyo 1 Uburyo bwibikorwa bya T irzepatide ^[6].

Ni ubuhe buryo bukoreshwa na T irzepatide?

Kuvura ubwoko bwa 2 metabolism: 

Tirzepatide yemerewe kuvura abarwayi bakuze bafite metabolism yo mu bwoko bwa 2 nk'umugereka w'imirire no gukora siporo. Ikigeragezo cya SURPASS cyerekanye ko Tirzepatide igabanya cyane urugero rwa hemoglobine A1c (HbA1c), kugabanuka kuva kuri -1.87% kugeza kuri -2.59% (-20 kugeza kuri 28 mmol / mol). Irerekana kandi igenzura ryiza rya glycemic ugereranije na GLP-1 yakira reseptor agoniste, nka semaglutide 1 mg mu rubanza rwa SUPRASS-2. Byongeye kandi, irashobora kugabanya ibiro byumubiri, hamwe no kugabanya ibiro kuva kuri -6.2 kugeza kuri -12.9 kg mubushakashatsi bwubuvuzi, ibyo bikaba bifite akamaro kanini kubarwayi bafite metabolism yo mu bwoko bwa 2 bakunze kugira ibibazo byinshi cyangwa umubyibuho ukabije ^[1,4].

Kuvura umubyibuho ukabije: 

Kubera ko Tirzepatide itera guhaga, igabanya gufata ibiryo, kandi igatera ibiro, ifite agaciro ko kuvura abarwayi bafite umubyibuho ukabije. Ubushakashatsi bwerekana ko bushobora kugabanya ibiro hejuru ya 20%, kuzamura imiterere y’abarwayi, no kuba uburyo bushya bwo kuvura umubyibuho ukabije, gufasha abarwayi bafite umubyibuho ukabije kugabanya ibiro no kugabanya ibyago by’indwara zitandukanye ziterwa n'umubyibuho ukabije ^[1,2].

Kugabanya ibyago byindwara zifata umutima: 

Abarwayi bafite metabolism yo mu bwoko bwa 2 bakunze guhura n'indwara nyinshi z'umutima. Usibye kugabanya isukari mu maraso n'uburemere, Tirzepatide igira ingaruka nziza ku bipimo bifitanye isano n'umutima n'imitsi, harimo kugabanya umuvuduko w'amaraso, kugabanya ibinure byo mu mitsi, no kugabanya urugero rwa triglyceride, bityo bigafasha kugabanya ibyago byo kwandura indwara z'umutima n'imitsi ndetse no kuzamura ingaruka z'umutima n'imitsi ^[4]..

Ubuvuzi bushobora kuvura steatohepatite itari inzoga (NASH): 

Tirzepatide ifite ingaruka zo kuvura NASH. Mugutezimbere insuline no kugenzura glucose na lipide metabolisme, irashobora kugabanya umwijima wo mu mwijima no gutwika, bigatanga icyerekezo gishya cyo kuvura NASH ^[5].

Umwanzuro

Nka GIP / GLP-1 dual reseptor agonist, Tirzepatide yerekanye akamaro gakomeye mukuvura metabolism nindwara ziterwa na metabolike. Mugutegeka gusohora insuline na glucagon, gutinda gusohora gastric, no kongera guhaga, bigabanya neza urugero rwa hemoglobine A1c kandi bikagabanya ibiro byabarwayi. Byongeye kandi, imiti itezimbere ingaruka z'umutima-damura nk'urwego rwa lipide n'umuvuduko w'amaraso kandi ikerekana imikorere muri steatohepatite itari inzoga.

Ibyerekeye Umwanditsi

Ibikoresho byavuzwe haruguru byose byakorewe ubushakashatsi, byahinduwe kandi byakozwe na Cocer Peptides.

Umwanditsi w'ikinyamakuru

De Block C ifitanye isano na kaminuza ya Antwerp hamwe n’ibigo bifitanye isano nayo mu Bubiligi, harimo Indashyikirwa ya Ctr Excellence, Ibitaro bya Kaminuza Antwerp (UZA na Univ Hosp Antwerp), hamwe na Infla Med Ctr Excellence. Ubushakashatsi bwe bukubiyemo amasomo menshi, nka Endocrinology & Diabete, aho yibanda ku misemburo n'indwara ya metabolike; Gastroenterology & Hepatology, ikora ubushakashatsi ku ndwara zifungura n'umwijima; Ubuvuzi rusange & Imbere mu Gihugu, bukemura ibibazo byo gusuzuma no gucunga indwara zisanzwe zimbere; Imirire & Dietetics, gukora iperereza ku mirire n'ingaruka zayo ku buzima; na Urology & Nephrology, biga ibijyanye na patologiya nubuvuzi bwindwara zinkari nimpyiko. Nintiti ifite uruhare runini mubice byinshi byubuvuzi. De Block C yanditse murutonde rwibisobanuro [4].

Imirongo ijyanye

[1] Wong E, Cope R, Dima L, n'abandi. Tirzepatide: Indwara ya Glucose iterwa na Insulineotropique Polypeptide na Glucagon-isa na Peptide-1 Agonist yo gucunga indwara ya Diyabete yo mu bwoko bwa 2 [J]. Ikinyamakuru cyo muri Amerika cyo kuvura, 2023,30 (1): e26-e35.DOI: 10.1097 / MJT.000000000000151588.

[2] Kumar D, Harshidha D, Mousigan M, n'abandi. Incamake kuri Tirzepatide, Uburyo bubiri bwo kuvura Diyabete n'umubyibuho ukabije [J]. Ikinyamakuru mpuzamahanga cyubushakashatsi bushya & Gukura, 2022,7: 983.DOI: 10.5281 / zenodo.7420605.

[3] Sweta, Gupta S, Bansal S, n'abandi. Tirzepatide igitabo gishya kirwanya diyabete ya molekile ikora ibikorwa bibiri [J]. Menya ubuzima rusange, 2024,21 (1): 75.DOI: 10.1186 / s12982-024-00200-2.

[4] De Block C, Bailey C, Wysham C, nabandi. Tirzepatide yo kuvura abantu bakuru bafite metabolism yo mu bwoko bwa 2: Icyerekezo cya endocrine [J]. Umubyibuho ukabije wa Diyabete & Diyabete, 2023,25 (1): 3-17.DOI: 10.1111 / dom.14831.

[5] Sood A, Kaur P, Syed O, n'abandi. Guhindura uburyo bwo kwita kuri metabolism: kwerekana ubushobozi bwa Tirzepatide mugucunga glycemic ndetse no hanze yacyo [J]. Impuguke zisubiramo Pharmacology Clinical, 2024,17 (3): 235-246.DOI: 10.1080 / 17512433.2024.2310070.

[6] Grover-Páez F, Gómez A, Suárez A, n'abandi. Uhereye ku buryo bwa glycocentricique kumurwayi ufite metabolism yo mu bwoko bwa 2 kugeza kuvura imiti myinshi no kugabanuka kwa neuro-nephro-cardiovasculaire. [M] // 2023.DOI: 10.5772 / intechopen.1002363.

INGINGO ZOSE N'AMAKURU Y’IBICURUZWA BITANZWE KURI URU RUBUGA BISANZWE KUBURANISHA AMAKURU N'INTEGO Z'UBUREZI.  

Ibicuruzwa byatanzwe kururu rubuga bigenewe gusa mubushakashatsi bwa vitro. Mu bushakashatsi bwa vitro (Ikilatini: * mu kirahure *, bisobanura mu bikoresho by'ibirahure) bikorwa hanze y'umubiri w'umuntu. Ibicuruzwa ntabwo ari imiti, ntabwo byemewe n’ikigo cy’Amerika gishinzwe ibiryo n’ibiyobyabwenge (FDA), kandi ntigomba gukoreshwa mu gukumira, kuvura, cyangwa gukiza indwara iyo ari yo yose y’ubuvuzi, indwara, cyangwa indwara. Birabujijwe rwose n'amategeko kwinjiza ibyo bicuruzwa mumubiri wabantu cyangwa inyamaswa muburyo ubwo aribwo bwose.